Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Despite advances in neurosurgery, chemotherapy and radiotherapy, glioblastoma remains
one of the most treatment-resistant CNS malignancies, and the tumour inevitably recurs. The …

Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Molecular classification has transformed the management of brain tumors by enabling more
accurate prognostication and personalized treatment. However, timely molecular diagnostic …

To follow the revision of the fourth edition of WHO classification and the recent progress on
the management of diffuse gliomas, the joint guideline committee of Chinese Glioma …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Glioblastoma multiforme (GBM) is the most common form of brain cancer and one of the
most aggressive cancers found in humans. Most of the signs and symptoms of GBM can be …

Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic
application is limited by toxic inflammatory responses. We assessed the safety and …